Premium
The effect of methylphenidate and prolintane on the metabolism of ethyl biscoumacetate
Author(s) -
Hague David E.,
Smith Marva E.,
Ryan Jerome R.,
McMahon F. G.
Publication year - 1971
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1971122part1259
Subject(s) - methylphenidate , prothrombin time , oral administration , placebo , metabolism , plasma levels , pharmacology , half life , drug , pharmacokinetics , medicine , anesthesia , chemistry , psychiatry , alternative medicine , attention deficit hyperactivity disorder , pathology
Following the oral administration of ethyl biscoumacetate to 12 patients and the determination of the half‐life of the drug and the plasma prothrombin time, either prolintane, methylphenidate, or placebo were orally administered in double‐blind fashion to the same patients for a period of 4 days. Twelve hours following the last administration, an identical dose of ethyl biscoumacetate was again administered and the half‐life and plasma prothrombin time again determined. The results presented here did not confirm a previous report that methylphenidate inhibits the metabolism of ethyl biscoumacetate. No significant difference could be found in the plasma half‐life of ethyl biscoumacetate before and after the 3 treatments. It is concluded that neither prolintane nor methylphenidate inhibit the metabolism of ethyl biscoumacetate in man.